COVID-19 ECMO patients face bleeding and clot risks, new study investigates
NCT ID NCT07352072
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks back at the medical records of 50 adult ICU patients with COVID-19 who needed a life-support machine called ECMO. The goal is to understand how often bleeding and dangerous blood clots happen, and how blood transfusions and blood thinners affect their care. The findings could help doctors make safer treatment decisions for these very sick patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this study could help doctors better manage bleeding and clotting risks in COVID-19 patients on ECMO, potentially improving survival and reducing complications.
What could go wrong
This is a small, single-center retrospective study that only looks back at past data. It cannot prove cause and effect, and results may not apply to all hospitals or patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of cardiothoracic anaesthsia and intensive care 4141
Copenhagen, 2100, Denmark
Contact Phone: •••-•••-•••• Email: •••••@•••••